Opinion/decision on a Paediatric investigation plan (PIP): Evusheld, tixagevimab,cilgavimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Infectious diseases, PIP…
- Invented name
Evusheld
- Active Substance
- Therapeutic area
Infectious diseases
- Decision number
P/0119/2023
- PIP number
EMEA-003079-PIP01-22
- Pharmaceutical form(s)
Solution for injection
- Condition(s) / indication(s)
- Prevention of Coronavirus disease 2019 (COVID-19)
- Treatment of Coronavirus disease 2019 (COVID-19)
- Route(s) of administration
- Intramuscular use
- Intravenous use
- Contact for public enquiries
- Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
